Estimating the Levels of Autoantibodies to NMDA And Dopamine Receptors in Children with Diabetes Mellitus Type I, Subject to the Condition Severity

Bykov Yu. V.
MD, PhD, Assistant, Chair for Anesthesiology, Resuscitation and Emergency Medicine; Anesthesiologist-resuscitator¹²

Baturin V. A.
Doctor of Medicine, Head, Chair for Clinical Pharmacology¹³

Uglova T. I.
MD, Pediatric Endocrinologist²

1 - Stavropol State Medical University, Stavropol, Russia
2 - City Clinical Children’s Hospital named after G. K. Filippsky, Stavropol, Russia
3 - LLC «Center for Clinical Pharmacology and Pharmacotherapy», Stavropol, Russia

Bykov Yuri; e-mail: yubykov@gmail.com

None declared.

The study had no sponsorship.

Type I Diabetes Mellitus (DM) is among the most common endocrinological diseases in adolescents. The purpose of this study was to research the level of autoantibodies (AAT) to NMDA receptors and Type 2 dopamine receptors (DAR2) in children with varying severity condition of Type I Diabetes. We examined 38 children and adolescents aged 2 to 17 years. In order to determine the levels of AAT to NMDA receptors and dopamine receptors (DR2) in blood serum, we applied the enzyme-linked immunosorbent assay (ELISA). We found higher levels of AAT to NMDA receptors and dopamine receptors (DAR2) in children with chronic Type I Diabetes against the background of diabetic ketoacidosis (DKA), as compared to children with the diabetes onset or compensation of the disease. The increased levels of AAT to NMDA and dopamine receptors (DAR2) were found in children and adolescents against the background of a long history of the disease and frequent hospitalization to the intensive care unit.

Diabetes Mellitus Type I, NMDA receptors, dopamine receptors, autoantibodies

10.29234/2308-9113-2020-8-4-41-48

1. Bao Y., Zhao T., Wang X. et al. Metabonomic variations in the drug-treated type 2 diabetes mellitus patients and healthy volunteers. J Proteome Res. 2009;8(4):1623-30. doi: 10.1021/pr800643w

2. Edge J.A., Ford-Adams M.E., Dunger D.B. Causes of death in children with insulin dependent diabetes 1990-96. Arch Dis Child. 1999; 81:318-323.

3. Lau A, Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch 2010; 460: 525-542. doi: 10.1007/s00424-010-0809-1

4. Lopes C.L., Pinheiro P.P., Barberena L.S., Eckert G.U. Diabetic ketoacidosis in a pediatric intensive care unit. J Pediatr (Rio J) 2017; 93(2): 179-184. doi: 10.1016/j.jped.2016.05.008

5. Lopez Vicchi F., Luque G.M., Brie B. et al. Dopaminergic drugs in type 2 diabetes and glucose homeostasis. Pharmacol Res. 2016;.109:.74-80. doi: 10.1016/j.phrs.2015.12.029

6. Robert A.A., Al-Dawish A., Mujammami M., Dawish M.A.A. Type 1 Diabetes Mellitus in Saudi Arabia: A Soaring Epidemic. Int J Pediatr. 2018; 2018:9408370. doi: 10.1155/2018/9408370

7. Sharma S, Singh H., Ahmad N., et al. The role of melatonin in diabetes: therapeutic implications. Arch Endocrinol Metab. 2015; 59(5): 391-9. doi: 10.1590/2359-3997000000098

8. Underland L.J., Mark E.R., Katikaneni R., Heptulla R. The Impact of Dopamine on Insulin Secretion in Healthy Controls. Indian J Crit Care Med. 2018; 22(4): 209-213. doi: 10.4103/ijccm.IJCCM­_175­_17

9. Watkins R.A., Evans-Molina C., Blum J.S., DiMeglio L.A.. Established and emerging biomarkers for the prediction of type 1 diabetes: a systematic review. Transl Res. 2014; 164(2): 110-21. doi: 10.1016/j.trsl.2014.02.004

10. Wojcik M., Sudacka M., Wasyl B. et al. Incidence of type 1 diabetes mellitus during 26 years of observation and prevalence of diabetic ketoacidosis in the later years. Eur J Pediatr. 2015;174: 1319-1324. doi: 10.1007/s00431-015-2537-1.